Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
Serum Institute of Indiato manufacture ~1 billion doses of NVX-CoV2373 in 2021
- Increases global manufacturing capacity for NVX-CoV2373 to over 2 billion annualized doses when at full capacity in 2021
- Agreement expands
Novavaxpartnership with world’s largest vaccine developer to increase global delivery of NVX-CoV2373
“Today’s agreement with
The agreement with SIIPL augments a global supply chain that will deliver over two billion doses of NVX-CoV2373 annually as of 2021.
The antigen component of NVX-CoV2373 is being manufactured at Novavax CZ in Bohumil,
- Biofabri in
- FUJIFILM Diosynth Biotechnologies (FDB) in both
North Carolinaand Texasin the United States
- FDB in the
- SIIPL in
- SK Bioscience in the
Republic of Korea
- Takeda Pharmaceutical Company Limited in
Novavax’ Matrix-M adjuvant is now being manufactured at
- AGC Biologics in
the United Statesand Denmark PolyPeptide Groupwill manufacture two key intermediaries used in Matrix-M in the United Statesand Sweden
“Signing of the manufacturing agreement with
NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In preclinical trials, NVX‑CoV2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In its Phase 1 portion of the Phase 1/2 clinical trial, NVX‑CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. Phase 2 clinical trials began in
Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
Serum is ranked as
The philanthropic philosophy of Serum continues with its work on newer vaccines and biologicals.
Learn more about
CEPI is an innovative partnership between public, private, philanthropic, and civil society organizations, launched at
Before the emergence of COVID-19 CEPI's priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).
Novavax Forward-Looking Statements
Statements herein relating to the future of
Source: Novavax, Inc.